Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Pip-Tokyo, Alfresa to Set Up SPD/Medical Materials JV House
October 4, 2004
- So-net M3 Sets Up Physicians' Job Change Site for Drug Houses
October 4, 2004
- DIAGNOSTIC NEWS IN BRIEF
October 4, 2004
- REGULATORY NEWS IN BRIEF
October 4, 2004
- WORLD NEWS IN BRIEF
October 4, 2004
- BUSINESS NEWS IN BRIEF
October 4, 2004
- IITs Involve Insurance-related Problems
October 4, 2004
- NEW PRODUCTS
October 4, 2004
- RESEARCH & DEVELOPMENT NEWS IN BRIEF
October 4, 2004
- CORPORATE ROUNDUP NEWS IN BRIEF
October 4, 2004
- GVP, GQP GLs Promulgated
October 4, 2004
- Korosho, Monkasho Hold Hearings on Promotion of Clinical Trials
October 4, 2004
- Only 6.9% of Medical Bills Processed Electronically
October 4, 2004
- GL for Treatment of Myasthenia Gravis Compiled
October 4, 2004
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
October 4, 2004
- IMSUT Embarks on Clinical Study to Predict Iressa's Effects
October 4, 2004
- PRESS SEMINAR
October 4, 2004
- Proper Use of Anti-cancer Drugs with Add'l Indications Called For
September 27, 2004
- Group to Promote Standardized Cancer Therapy Holds 1st Meeting
September 27, 2004
- 60% of Respondents Support Acceptance of Qualified Foreign Nurses: Survey
September 27, 2004
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…